General Description of Generic Cymbalta
What Is Cymbalta?
Cymbalta is indicated for the treatment of major depressive disorder, as well as for the management of diabetic peripheral neuropathic pain (DPNP).
Cymbalta offers relief from both the emotional and physical symptoms that are associated with depression. It works to help restore the balance and increase the levels of two naturally occurring chemicals in the brain and body that experts believe are related to both depression and diabetic peripheral neuropathic pain (DPNP).
How Cymbalta Works
Cymbalta works to help restore the balance of two naturally occurring chemicals in the brain and body: serotonin and norepinephrine. Research suggests that these chemicals play a role in both depression and diabetic peripheral neuropathic pain (DPNP).
In the brain, serotonin and norepinephrine are associated with transmission of thoughts and feelings. Throughout the body, these chemicals help "turn down" the volume of pain signals. If these chemicals are out of balance, you may experience emotional symptoms, like depressed mood, or physical symptoms, like aches and pains.
Cymbalta helps restore both serotonin and norepinephrine. By addressing both, Cymbalta effectively relieves a broad range of depression symptoms. Cymbalta also effectively manages diabetic peripheral neuropathic pain (DPNP).
How Can Cymbalta Help?
Cymbalta has been approved by the FDA for the treatment of major depression, as well as the management of diabetic peripheral neuropathic pain (DPNP). Cymbalta is available in pharmacies.
Cymbalta addresses both the emotional and physical symptoms of depression. In clinical studies, many people began to show improvement in both emotional and physical symptoms in as early as one to four weeks. However, results may vary from person to person.
In a separate clinical study, many people suffering from diabetic peripheral neuropathic pain (DPNP). felt significant relief in as little as one week, with continued improvement over the 12-week course. Patients also felt significant pain relief at night in as little as one week, with continued improvement over the 12-week course.
Of course, Cymbalta is not for everyone. As with any prescription medication, it helps to be aware of the most common side effects and potential risks associated with treatment. For complete product information refer to the full prescribing information.
Precautions for Taking Cymbalta
You should NOT take Cymbalta if:
- You are allergic to duloxetine hydrochloride or other ingredients in Cymbalta.
- You currently or have recently taken a monoamine oxidase inhibitor (MAOI).
- You are taking thioridazine.
- You have uncontrolled narrow-angle glaucoma.
Depression, as a disease, can be associated with periods when the symptoms can worsen or thoughts of suicide can emerge. If you have thoughts of suicide, call your physician immediately. Patients and their families should watch for these as well as for anxiety, agitation, panic, difficulty sleeping, irritability, hostility, aggressiveness, impulsivity, restlessness or overexcitement and hyperactivity. Call the doctor if any of these are severe or occur suddenly. Be especially observant at the beginning of antidepressant treatment or whenever there is a change in dose.
Tell your doctor if you:
- Have serious liver or kidney problems or glaucoma.
- Are pregnant or nursing.
- Consume large quantities of alcohol.
- Are taking other prescription or nonprescription medications.
If you have questions, talk to your doctor before taking Cymbalta.
For additional safety information, please refer to the full prescribing information for healthcare professionals (PDF: 77KB).
Possible Side Effects of Cymbalta
In clinical studies for depression, the most common side effect when taking Cymbalta was nausea. For most people, the nausea was mild to moderate, and usually subsided within one to two weeks. Other common side effects were dry mouth, constipation, decreased appetite, fatigue, sleepiness, and increased sweating. Most people were not bothered enough by side effects to stop taking Cymbalta. Your doctor may periodically check your blood pressure while you are taking Cymbalta.
In clinical studies for diabetic peripheral neuropathic pain (DPNP), the most common side effect when taking Cymbalta was nausea. For most people, the nausea was mild to moderate, and usually subsided within one to two weeks. Other common side effects were sleepiness, dizziness, constipation, diarrhea, dry mouth, increased sweating, decreased appetite, and muscle weakness. Most people were not bothered enough by side effects to stop taking Cymbalta. Your doctor may periodically check your blood pressure while you are taking Cymbalta.
Welcome to Cymbalta News
Cymbalta News is commited to providing news and information about Cymbalta, the new SSRNI from Eli Lilly.
Cymbalta works to treat more than one condition. Cymbalta has been approved by the FDA for both the treatment of depression and the management of pain associated with diabetic peripheral neuropathy. Cymbalta (an SSNRI) targets two chemicals, serotonin and norepinephrine, that are believed to play a role in how the brain and body affect mood and pain.
Cymbalta and Depression
Cymbalta offers relief for the emotional and physical symptoms associated with depression. It may help restore the balance of two naturally occurring chemicals in the brain and body that experts believe are related to major depressive disorder.
Many antidepressants target one chemical, serotonin. Cymbalta also targets a second chemical, norepinephrine. In clinical trials, Cymbalta was proven effective in treating depression, both its emotional and physical symptoms.
In clinical studies, many people began to show improvement in emotional and physical symptoms as early as one to four weeks.
Cymbalta for Pain Relief of DPNP
Cymbalta has been approved by the FDA for the management of diabetic peripheral neuropathic pain (DPNP).
Cymbalta is an FDA-approved treatment for the management of pain associated with diabetic peripheral neuropathy. Cymbalta doesn't undo or stop nerve damage, and it can't make diabetes go away.
Cymbalta acts as a pain reducer due to its effect on two naturally occurring chemicals in the central nervous system, serotonin and norepinephrine.
Many people suffering from diabetic peripheral neuropathic pain (DPNP) can receive significant pain relief in as little as one week. Patients on a study felt improvement during the entire length of the 12-week study. Patients also felt significant pain relief at night in as little as one week, with continued improvement over the suration of the study.
Recent Cymbalta News & Press Releases
Generic Cymbalta Available for Sale
United Pharmacies are now selling Generic Cymbalta with prices starting at $7.00 per strip of 10 tablets. Symbal is manufactured by manufactured by Torrent Pharmaceuticals and is available in 20mg, 30 mg and 40mg dosages.
Generic Cymbalta to be Manufactured by Torrent Pharmaceuticals
Torrent Pharmaceutical have announced they will manufacture Generic Cymbalta. the new drug will be called Symbal and will be available in 20mg, 30mg and 40mg dosages. ]
FDA Approves Cymbalta for the Treatment of Depression
Prescription Cymbalta is not for everyone. People who are allergic to duloxetine hydrochloride or the other ingredients in Cymbalta should not take it. If you are taking thioridazine or if you are taking or have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take Cymbalta.
EU Scientific Committee Recommends Approval of Cymbalta® and Xeristar® for Treatment of Major Depressive Episodes
Eli Lilly and Company and Boehringer Ingelheim today announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes. The CHMP has recommended that the European Commission authorize the drug to be marketed. If approved, this pharmaceutical treatment for depression will be marketed throughout the European Union by Lilly under the brand name Cymbalta® and by Boehringer Ingelheim under the brand names Cymbalta and, in Greece, Italy and Spain, as Xeristar®.
Drug May Avert Surgery for Severe Incontinence
Women awaiting surgery to relieve severe stress urinary incontinence may gain significant relief with the drug, leading some to reconsider surgery, a study indicates. Cymbalta (Duloxetine) has previously been shown to be effective in women with mild to moderate stress urinary incontinence.
New Antidepressant Targets Physical Symptoms Too
Depression is more than mood. It can come with physical symptoms that might surprise you. The government has approved a new antidepressant called Cymbalta designed to attack the emotional problem and more. "But it treated the physical symptoms that I have, that I had all the way along with my depression, pain in my shoulders, back and neck," says Randi Bradstreet, a Cymbalta patient.
New Antidepressant Aids Fibromyalgia Sufferers
A new antidepressant called duloxetine improved symptoms of fibromyalgia -- a chronic and painful musculoskeletal disorder in women.
Cymbalta Approved for Diabetic Peripheral Neuropathy Pain (DPNP)
The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy. Cymbalta comes in a capsule and can be taken once a day. The recommended daily dose for Cymbalta is 60 mg. In addition to depression and pain caused by diabetic peripheral neuropathy, duloxetine hydrochloride, the active ingredient in Cymbalta, also has been approved in Europe for the treatment of moderate to severe stress urinary incontinence, another condition believed to respond to treatment that affects serotonin and norepinephrine levels.
Read More Eli Lilly and Company Announces FDA Approval of Cymbalta, a New Antidepressant Medication
The U.S. Food and Drug Administration has approved Cymbalta® (Duloxetine Hydrochloride), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company announced today. Cymbalta, a balanced and potent reuptake inhibitor of serotonin and norepinephrine, has been studied in more than 6,000 adults with major depression worldwide. Its approval gives healthcare professionals and patients a long-awaited new option for treating the broad range of emotional and physical symptoms of depression.